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Serotonin has been thought to be pivotal in migraine
pathogenesis since the early days of headache research.
Sicuteri (1) and Lance (2) were pioneers in unraveling
that serotonin metabolism was disturbed in migraine,
and their ﬁndings were conﬁrmed with reﬁned methods
by Ferrari and Bruyn (3). Those data pointed toward a
cycling proﬁle of 5-HT metabolism: a decreased dispos-
ition and enhanced metabolism leading to serotonergic
receptor supersensitivity between attacks, contrasting
with serotonin release and transiently decreased turn-
over during attacks. The major shortcomings of these
early studies are that they chieﬂy explored systemic
5-HT metabolism in blood and urine and assumed
that the same changes would occur in brain 5-HT
metabolism. The development by Diksic and collabor-
ators (4) of a method that measures trapping by the
brain of the radio-labeled precursor of 5-HT synthesis,
a-[11C] methyl-L tryptophan (11C-AMT), to evaluate
central 5-HT synthesis was a major advance for patho-
genic studies in migraine and other brain disorders.
Surprisingly, since the development of this method
35 years ago, only three studies have been performed
in migraine: one by Chugani et al. (5), and two by Sakai
et al., including the one published in this issue of
Cephalalgia on the eﬀect of eletriptan on 11C-AMT
brain uptake (6). The results are only partly concord-
ant, even in the studies coming from the same group.
In the article published in this issue, Sakai et al. (6)
report that the PET-detected brain trapping of
11C-AMT, expressed as the K complex (K*) and
thought to reﬂect 5-HT synthesis capacity in the
brain, is signiﬁcantly decreased (20%) 1 hour after
40mg eletriptan p.o. in six female migraineurs studied
interictally, whereas there is a mild non-signiﬁcant
increase in six healthy control participants. The eletrip-
tan-induced decrease predominates in the upper dorsal
brainstem, superior parietal, parahippocampal and
occipital cortices. Sakai et al. (6) explain their ﬁndings
by an increased sensitivity of 5-HT1A and 5-HT1B
autoreceptors caused by a chronic interictal hyposero-
tonergic state. It is known that activation of these auto-
receptors decreases 5-HT release and synthesis, and
there is indirect evidence for interictal low, but ictally
heightened, 5-HT neurotransmission in migraine
(review in 7). The eﬀects of eletriptan are in line with
those published by the same authors (8) showing that
sumatriptan injected during an attack produces a 33%
reduction of 11C-AMT uptake. The increase of the
latter found after preventive treatment with beta-block-
ers in migraine patients (5) could be the counterpart, as
beta-blockers are able to antagonize 5-HT1A receptors
(see 5). That 5-HT receptors/transporter can be upre-
gulated interictally in migraine was evidenced by two
PET studies showing increased 5-HT1A receptor (9)
and 5-HT transporter (10) availabilities in brain and
brainstem, respectively. Nonetheless, to conﬁrm that
the eletriptan eﬀect is caused by hypersensitivity of
5-HT1A/B autoreceptors, studies using speciﬁc recep-
tor agonists/antagonists would be necessary.
Sakai et al. (6) found no signiﬁcant diﬀerence in
11C-AMT uptake between migraine patients interictally
(K*: 5.7 ml/g/min) and healthy control participants (K*:
5.0). This is somewhat surprising as the same authors
reported K*values previously of 4.71 in migraineurs
between attacks (8) and 7.7 and 6.6 in healthy females
and males (11), which would suggest reduced 5-HT syn-
thesis in migraine and ﬁt the authors’ hypothesis of a
low serotonergic state with receptor upregulation. The
ﬁnding by Chugani et al. (5) that K* values were clearly
greater in 11 migraine patients interictally (7.75) than in
healthy control participants (5.46), is in line with the
trend for a regionally more marked increase of 5-HT
synthesis in migraine reported in this issue (6). Sakai
et al. (6) explain the apparent paradox by similar prox-
imal rate limiting mechanisms in migraine and in con-
trol subject participants but diﬀerent distal feedback
mechanisms including autoreceptor sensitization.
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One cannot exclude, however, other confounding
factors related to methodological issues. A shortcoming
of all three studies performed in migraine up to now is
that none of them controlled for occurrence of an
attack after the PET recording. It is known that both
clinical premonitory symptoms and central nervous
system changes may occur 24 hours or more before
the migraine attack and that changes in serotonin
metabolism and transmission are likely to follow the
same temporal pattern (7). K* values could vary
depending on whether they are (6,8) or are not (5) cor-
rected for unlabeled free plasma tryptophan levels.
Although 11C-AMT uptake in brain areas is propor-
tional to their 5-HT content, the major part of
11C-AMT is not metabolized into a-methyl 5-HT. A
large AMT pool remains unmetabolized or is diverted
towards the kynurenin pathway (12). Under normal
circumstances, the metabolites of this pathway are in
a 1/100 to 1/1000 ratio over brain tryptophan, while the
sum of 5-HT and its metabolite 5-HIAA are one-ﬁfth of
the brain’s concentrations of tryptophan. However,
after inﬂammation or ischemia, metabolites of the
kynurenin pathway may markedly increase because of
induction of their synthesizing enzymes (12). Whether
this may also occur in migraine is not known.
Whatever the limitations of the 11C-AMT PET
method may be, it still remains the only way, although
indirect, to evaluate in vivo serotonin metabolism in the
human brain. Until better radio-labeled tracers and/or
techniques become available, it seems worthwhile to
explore further the role of 5-HT in migraine along the
same path, paying greater attention to the migraine
cycle, the eﬀect of antimigraine drugs and the correl-
ation with neurophysiological data and genetics.
Our masters did not wait for more extensive data on
brain serotonin in their patients to jump ahead and
develop novel drugs that interfered with serotonergic
transmission and were eﬀective in migraine prevention
(13,14). Interestingly, methysergide, one of these drugs,
remains one of the most eﬀective prophylactic treat-
ments in 2013. Unfortunately, 2013 may also be the
last year of its commercial use, as the European
Medicines Agency is planning to take methysergide
oﬀ the market, although the complication of ﬁbrosis
does not occur if the guidelines for use are followed,
that is 6 months of treatment alternating with 1 month
of drug holiday, and the majority of my fellow migrai-
nologists strongly support the drug.
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